You are here

Instrumentation enabling a 16-fold decrease in oligonucleotide cost

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AG044863-01
Agency Tracking Number: R43AG044863
Amount: $698,866.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIA
Solicitation Number: PA12-088
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
United States
DUNS: 808473453
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (503) 446-4055
Business Contact
Phone: (503) 445-7757
Research Institution

DESCRIPTION (provided by applicant): Although balance and gait disorders are one of the most common and devastating chronic medical problems of older people, especially those with chronic neurological diseases, clinicians or clinical researchers do not measure balance and gait frequently, accurately, or sensitively. Our long-term goal is to develop and commercialize a unique system called the Home Objective Mobility Exam (HOME) to allow patients to measure their own balance and gait at home. If physiciansand physical therapists could obtain frequent, accurate, self-administered measures of balance and gait characteristics, then they will be able to earlier predict fall risk and changes in mobility. This will also enable them to quickly improve interventions in order to prevent mobility disability. The objective of this application is to deveop a novel method to allow patients to quantify their own standing balance, gait and turning with a quick, simple, and extremely easy to use system. The specifc aims are: Aim I. To develop a new version of the Opal movement monitor for home use. The objective of this aim is to transform the Opal sensors from a computer-based clinician/researcher-controlled system to a nonprofessional/patient-controlled system of movementmonitoring. Aim II. To determine the feasibility, validity and reliability of having people with Parkinson's disease test their own balance and gait at home. We hypothesize that balance and gait, measured by patients in their homes, will be valid and reliable compared with measures administered by research assistants and with clinical scales and show very good test-retest reliability. We will initially develop HOME for patients with Parkinson's disease because they have more falls than any other neurological disorder, but we are confident that this tool will be useful for patients any form of mobility disability, such as multiple sclerosis, stroke, head injury, developmental disorders, multisensory deficits, frail elderly, etc. Based on results of this proposal, our Phase II application will thentest the ability of the HOME to more quickly detect changes in balance and gait following a change in medication or physical therapy, compared to usual care, in preparation for FDA approval and widespread marketing.PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: This project allows APDM to determine the feasibility of developing a self-administered balance and gait test for patients with mobility disability, using the core technology of our company: theworld's most advanced body-worn inertial sensors, Opals. This novel, Home Objective Mobility Exam (HOME) will uniquely provide information about day-to-day variability, daily fluctuations, and ecological effects on gait and balance to physicians, physicaltherapists, and clinical trialists so they can more quickly improve interventions to prevent or limit mobility disability.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government